Synmosa Biopharma Corporation (TPEX:4114)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
36.75
+0.40 (1.10%)
Jul 24, 2025, 11:57 AM CST
1.10%
Market Cap18.20B
Revenue (ttm)5.72B
Net Income (ttm)710.08M
Shares Out500.70M
EPS (ttm)1.52
PE Ratio23.91
Forward PE15.80
Dividend0.55 (1.50%)
Ex-Dividend DateJul 11, 2025
Volume44,000
Average Volume1,637,595
Open36.65
Previous Close36.35
Day's Range36.00 - 36.95
52-Week Range24.33 - 36.80
Beta-0.04
RSI79.50
Earnings DateAug 11, 2025

About Synmosa Biopharma

Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches, develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan. The company offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, sex hormones, and other forms. In addition, it offers contract manufacturing... [Read more]

Sector Healthcare
Founded 1970
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4114
Full Company Profile

Financial Performance

In 2024, Synmosa Biopharma's revenue was 5.55 billion, an increase of 7.96% compared to the previous year's 5.14 billion. Earnings were 684.68 million, an increase of 15.11%.

Financial Statements

News

There is no news available yet.